Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4472461
Max Phase: Preclinical
Molecular Formula: C29H35FN4O9
Molecular Weight: 602.62
Molecule Type: Unknown
Associated Items:
ID: ALA4472461
Max Phase: Preclinical
Molecular Formula: C29H35FN4O9
Molecular Weight: 602.62
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C=C1C(=O)O[C@H]2[C@H]1CC/C(COC(=O)CCC(=O)N1CCN(C(=O)Cn3cc(F)c(=O)[nH]c3=O)CC1)=C\CC[C@@]1(C)O[C@@H]21
Standard InChI: InChI=1S/C29H35FN4O9/c1-17-19-6-5-18(4-3-9-29(2)25(43-29)24(19)42-27(17)39)16-41-23(37)8-7-21(35)32-10-12-33(13-11-32)22(36)15-34-14-20(30)26(38)31-28(34)40/h4,14,19,24-25H,1,3,5-13,15-16H2,2H3,(H,31,38,40)/b18-4+/t19-,24-,25-,29+/m0/s1
Standard InChI Key: OFIFYYMGHYMFLA-DNAUFTMUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 602.62 | Molecular Weight (Monoisotopic): 602.2388 | AlogP: 0.43 | #Rotatable Bonds: 7 |
Polar Surface Area: 160.61 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 13 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 8.12 | CX Basic pKa: | CX LogP: 0.04 | CX LogD: -0.03 |
Aromatic Rings: 1 | Heavy Atoms: 43 | QED Weighted: 0.20 | Np Likeness Score: 0.79 |
1. Ding Y, Li S, Ge W, Liu Z, Zhang X, Wang M, Chen T, Chen Y, Zhang Q.. (2019) Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma., 183 [PMID:31553932] [10.1016/j.ejmech.2019.111706] |
Source(1):